ARTICLE | Clinical News
RHB-104: Phase III started
October 7, 2013 7:00 AM UTC
RedHill began the double-blind, placebo-controlled, international Phase III MAP US trial to evaluate oral RHB-104 twice daily for 52 weeks in about 240 patients with moderately to severely active CD. ...